Teresa Morán - Concepedia

Author

Teresa Morán

Also Known As

Mireia Morgades, Moran, Teresa, T Moran, T. Moran, T. Morán, T.M. Moran, T.M. Teresa Moran, Teresa Moran, Teresa Morán, Teresa Morán

323

Publications

18.5K

Citations

H-Index

Concepts

All Affiliations

Institut Català d'Oncologia Hospital Universitari Germans Trias i Pujol Universitat Autònoma de Barcelona Hospital General Universitario de Alicante Doctor Balmis Hospital Clínico Universitario Lozano Blesa

About

Teresa Morán is an author at Institut Català d'Oncologia specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	56	9.1K
2	Public Health	4	4	346
3	Health Sciences	3	3	91
4	Engineering	2	2	96
5	Natural Sciences	1	1	21

Teresa Morán

Publications

17.8K

Citations

H-Index

Page 1

	Year	Citations
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Rafael Rosell, Enric Carcereny, Radj Gervais, The Lancet Oncology OncologyStandard ChemotherapyRandomised Phase 3PathologyBronchial Neoplasm	2012	5.5K
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer Rafael Rosell, Teresa Morán, Cristina Queralt, New England Journal of Medicine	2009	2.4K
<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis Justin F. Gainor, Alice T. Shaw, Lecia V. Sequist, Clinical Cancer Research	2016	1.2K
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer Matthew J. Niederst, Lecia V. Sequist, John T. Poirier, Nature Communications	2015	619
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer Hiroyuki Yasuda, Eunyoung Park, Cai-Hong Yun, Science Translational Medicine	2013	548
Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study Gemma Gatta, Laura Botta, María‐José Sánchez, European Journal of Cancer OncologyEarly 2000SEpidemiology Of CancerPathologyCancer Diagnosis	2015	474
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor <i>BRAF</i> gene mutations but lack mutations in <i>KRAS, NRAS,</i> or <i>MEK1</i> Kadoaki Ohashi, Lecia V. Sequist, Maria E. Arcila, Proceedings of the National Academy of Sciences	2012	434
Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer Enriqueta Felip, Rafael Rosell, J Maestre, Journal of Clinical Oncology	2010	418
Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer Mariano Provencio, Ernest Nadal, J.L. González-Larriba, New England Journal of Medicine	2023	397
Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas Miguel Tarón, Yukito Ichinose, Rafael Rosell, Clinical Cancer Research	2005	336

Page 1